OCGN trades 400.0% below Wall Street's consensus target of $5.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes OCGN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Ocugen, Inc. (OCGN) has a Wall Street consensus price target of $5.00, based on estimates from 6 covering analysts. With the stock currently trading at $1.00, this represents a potential upside of +400.0%. The company has a market capitalization of $339M.
Analyst price targets range from a low of $3.50 to a high of $6.00, representing a 50% spread in expectations. The median target of $5.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, OCGN trades at a trailing P/E of -4.3x. Analysts expect EPS to grow -7.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 REPLReplimune Group, Inc. | $1.1B | $12.96 | $18.67 | +44.1% | Buy | — | 15 |
 EDITEditas Medicine, Inc. | $413M | $2.69 | $4.00 | +48.7% | Buy | — | 25 |
 BEAMBeam Therapeutics Inc. | $2.5B | $24.37 | $59.50 | +144.2% | Buy | — | 27 |
 NTLAIntellia Therapeutics, Inc. | $1.4B | $12.33 | $23.00 | +86.5% | Buy | — | 39 |
 CRSPCRISPR Therapeutics AG | $5.4B | $55.76 | $67.83 | +21.6% | Buy | — | 38 |
 RCKTRocket Pharmaceuticals, Inc. | $330M | $3.02 | $9.00 | +198.0% | Buy | — | 19 |
 ADVMAdverum Biotechnologies, Inc. | $96M | $4.36 | — | — | — | — | — |
 BOLDBoundless Bio, Inc. | $61M | $2.70 | — | — | — | — | — |
 JANXJanux Therapeutics, Inc. | $1.0B | $16.52 | $28.25 | +71.0% | Buy | — | 16 |
 REGNRegeneron Pharmaceuticals, Inc. | $82.6B | $801.82 | $827.71 | +3.2% | Buy | 14.7x | 49 |
Quick answers to the most common questions about buying OCGN stock.
The consensus Wall Street price target for OCGN is $5, representing 400.0% upside from the current price of $1. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
OCGN has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $5 implies 400.0% upside from current levels.
OCGN's current price is $1 with a consensus target of $5 (400.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for OCGN, while the most conservative target is $3.5. The consensus of $5 represents the median expectation. These targets typically reflect 12-month expectations.
OCGN is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month OCGN stock forecast based on 6 Wall Street analysts shows a consensus price target of $5, with estimates ranging from $3.5 (bear case) to $6 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on OCGN, with a "Buy" consensus rating and $5 price target (400.0% upside). 5 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
OCGN analyst price targets range from $3.5 to $6, a 50% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.